Efferocytosis-inspired nanodrug treats sepsis by alleviating inflammation and secondary immunosuppression.
Xiaoyu GuoPeiming ShenRongjiao ShaoTing HongWeizhuo LiuYi ShenFan SuQinlan WangBin HePublished in: Biomedical materials (Bristol, England) (2023)
Uncontrolled inflammation storm induced by sepsis may lead to severe organ dysfunction and secondary immunosuppression, which is one of the main reasons for high mortality and prolonged hospitalization of septic patients. However, there is a lack of effective treatments for it at present. Here, we report an efferocytosis-inspired nanodrug (BCN@M) to treat sepsis and secondary immunosuppression via regulating the macrophage function. Bioactive molecular curcumin was loaded with bovine serum albumin (BSA) and then coated with the damaged erythrocyte membrane derived from septic mice. It was found that the septic erythrocytes promoted the efferocytosis signal and BCN@M uptake efficiency by macrophages. The well-constructed BCN@M nanodrug reduced the hyperinflammation in sepsis and restored the bacterial clearance ability of macrophage in the secondary immunosuppression state. This study highlights BCN@M as an efferocytosis-inspired nanodrug to alleviate hyperinflammation and secondary immunosuppression of sepsis.
Keyphrases
- acute kidney injury
- septic shock
- intensive care unit
- oxidative stress
- adipose tissue
- ejection fraction
- newly diagnosed
- end stage renal disease
- type diabetes
- cardiovascular events
- cardiovascular disease
- drug delivery
- prognostic factors
- wastewater treatment
- cancer therapy
- patient reported outcomes
- coronary artery disease
- skeletal muscle
- metabolic syndrome
- insulin resistance
- wound healing
- patient reported